Track Cadrenal Therapeutics Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cadrenal Therapeutics Inc. Common Stock CVKD · Stock Open Cadrenal Therapeutics Inc. Common Stock in new tab

1.09 USD
Add to portfolio
EPS
-5.02
P/B
0.82
ROE
-275.16
Beta
1.84
Target Price
14.00 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 9, 2026
EPS-5.02
Book Value1.32
Price to Book0.82
Debt/Equity0.07
% Insiders11.928%
Estimates
Forward P/E-0.32
Forward EPS-3.41
Target Mean Price14.00

DCF Valuation

Tweak assumptions to recompute fair value for Cadrenal Therapeutics Inc. Common Stock (CVKD)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Cadrenal Therapeutics Inc. Common Stock Logo Cadrenal Therapeutics Inc. Common Stock Analysis (CVKD)

United States Health Care Official Website Stock

Is Cadrenal Therapeutics Inc. Common Stock a good investment? Cadrenal Therapeutics Inc. Common Stock (CVKD) is currently trading at 1.09 USD. Market analysts have a consensus price target of 14.00 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cadrenal Therapeutics Inc. Common Stock is expected to release its next earnings report on Nov. 9, 2026. The market consensus estimate for Forward EPS is -3.41.

Investor FAQ

Does Cadrenal Therapeutics Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cadrenal Therapeutics Inc. Common Stock?

Cadrenal Therapeutics Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 9, 2026. The company currently has a trailing EPS of -5.02.

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company that develops novel therapies for life-threatening immune and thrombotic conditions. The company is developing Tecarfarin, an oral vitamin K antagonist that is in Phase 3 clinical trial designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, and atrial fibrillation; CAD-1005, a first-in-class 12-LOX inhibitor for the treatment of heparin-induced thrombocytopenia, a deadly immune-mediated thrombotic disorder that has completed Phase 2 clinical trial; and Frunexian, a parenteral clinical-stage factor XIa inhibitor designed for use in acute hospital settings that has completed Phase 1 clinical trial. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. The company was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Exchange Ticker
NMS (United States) CVKD
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Aug. 20, 2024 0.07
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion